1 / 25

Horizon scanning Hypothermic Machine Perfusion & Normothermic Machine Perfusion

Horizon scanning Hypothermic Machine Perfusion & Normothermic Machine Perfusion. Gabriel C. Oniscu Consultant Transplant Surgeon Honorary Clinical Senior Lecturer NRS Career Research Fellow Royal Infirmary of Edinburgh . Surgical techniques. Surveillance. Immunossupression.

kieu
Download Presentation

Horizon scanning Hypothermic Machine Perfusion & Normothermic Machine Perfusion

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Horizon scanningHypothermic Machine Perfusion&Normothermic Machine Perfusion Gabriel C. Oniscu Consultant Transplant Surgeon Honorary Clinical Senior Lecturer NRS Career Research Fellow Royal Infirmary of Edinburgh

  2. Surgical techniques Surveillance Immunossupression No significant changes NORS • Organ preservation • Transplant 50% increase CLOD network SNOD network Cold static storage • Organ • donation • Organ • retrieval

  3. Oxygen carriers Hypothermic perfusion Blood perfusate Normothermic perfusion Pulsatile perfusion Oxygenated perfusion In-situ Ex-situ Sub-normothermic perfusion Pre-conditioning Reconditioning

  4. The drivers of change

  5. Increased utilisation of ECD and DCD • Lower organ recovery rate • Higher rate of complications • Poorer long term organ function • Logistic constrains • Cost benefit

  6. Machine perfusionEvaluation criteria • Better outcome • Prediction of function • Expansion of organ pool • Organ reconditioning • Ease of implementation • Costs

  7. Evolution of the HMP

  8. Evidence for HMP?

  9. Reduced DGF in MP group (21% vs 27%) • Shorter period of DGF • Lower risk of graft failure • Better one year survival

  10. NO survival benefit in DCD (despite a lower DGF)

  11. Watson et al, AJT 2010

  12. Systematic review • 5 RCT • One cohort study • One registry study • 4 data review • 844 MP (381 in RCT) • ? Clinical effectiveness …Depends on which trial data is used Bond et al, Health Technology Assessment 2009; 13:38

  13. Cost effectiveness? • SCS is cheaper • DGF related dialysis costs: 7,581$ vs 4,390 • MP is better in the long run (survival) Groen et al. Am J Transplant 2012;12:1624-1630 • USRDS and Medicare • MP associated with $2130 lower hospital costs and lower DGF • No difference in long term Medicare costs • ? MP utilisation or population differences Buchanan et al. Am J Transplant 2008;8:2391-401.

  14. Graft assessment? • MP trial data • 111 Older donor kidneys (>55) • Lipid peroxidation markers predict DGF Nagelschmidt et al. J Surg Res 2013;180:337-42. • MP trial data • 306 donor kidneys • GST, NAG and H-FABP predict DGF Moers et al. Transplantation 2010;90:966-703.

  15. PNF: no difference • PS/ GS: no difference • Lower early dysfunction rates (5% vs 25%) • Biliary complications 10% vs 20% • Shorter hospital stay Guarrera et al. Am J Transplant 2010

  16. First Results on End-Ischemic Hypothermic Oxygenated Machine Perfusion (HOPE) of Human Liver Grafts Donated after Cardiac Arrest. Philipp Dutkowski, Andrea A. Schlegel, Michelle DeOliveira, Olivier DeRougemont, Fabienne Neff, Pierre-Alain Clavien. Department of Surgery& Transplantation, University Hospital Zurich, Zurich, Switzerland. • 5 DCD livers • Early function comparable with DBD • No biliary complications in the first 6 months

  17. 90 min CA and HMP vs CS • Hepatocellular injury and function improved with HMP • Significant endothelial cell and Kupfer cell injury • Progressive lesions 24-48h post-reperfusion leading to graft failure

  18. Normothermic machine perfusion

  19. Normothermic perfusion • Bridge between asystole and organ transplantation • In the donor • Ex situ • Rehabilitation at a cellular level (replenish mitochondrial stores of ATP) • Dynamic organ assessment • Organ modulation?

  20. NRP and kidney Tx • Function comparable with living donors and DBD kidneys • Lower rate of DGF • Increases organ pool (DCD II) • Expansion of acceptance criteria

  21. NRP and liver Tx • IC rates: 5-10% • 80% graft survival • PNF rates 1/10 and 2/20 • Liver recovery rate 25-50% (DCD II)

More Related